Pan-Cancer Markers Validated on Human Cancers
Pan-cancer markers contribute to the development of universal diagnostic strategies, allowing for the identification of common genetic mutations across diverse cancers, such as the detection of shared pathways implicated in tumorigenesis.
Offering over 300 primary antibodies validated on human cancer tissue and cells, we aim to support proteomic studies, complementing genomics, and unveiling additional insights into pathways and processes driving human cancer biology.
With validation on human cancers and numerous cancer cell lines (data available on the Human Protein Atlas portal), our primary antibodies offer comprehensive coverage and enhanced validation for reliable results. Their versatility extends to multiple applications, ensuring they meet the diverse needs of your research projects.
Why Proteomic Matters?
Genomic and transcriptomic analyses, while comprehensive, may not fully capture the intricate complexity of cancer. Proteins, serving as the effectors of genomic functions, play a crucial role in orchestrating intricate molecular processes within cells.
Thus, integrating proteomic studies with genomics and transcriptomics introduces a novel paradigm, enabling the elucidation of hidden and undetected facets of human cancer biology.
Join us in unlocking the potential of proteomic phenotyping in cancer research. Together, let's advance our understanding of cancer biology and contribute to the development of targeted therapies.